Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Indomethacin Versus Nifedipine for Preterm Labor Tocolysis

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2014 by Stanford University
Information provided by (Responsible Party):
Stanford University Identifier:
First received: June 13, 2007
Last updated: November 18, 2014
Last verified: November 2014

Indomethacin and Nifedipine are commonly used medications for treatment of pre term labor. This study will compare the efficacy and adverse outcomes of oral nifedipine versus oral indomethacin for preterm labor tocolysis in an effort to identify which drug is most effective.

Patients diagnosed with preterm labor who grant consent will be randomized by the pharmacy to receive oral nifedipine or oral indomethacin. Both the patient and primary medical provider will be blinded to the identity of the study drug. An abdominal ultrasound will be performed in the labor and delivery unit prior to the administration of the tocolytic in order to assess fetal position and fluid level, and to document fetal cardiac activity and movement, and will be repeated at 48 hours post-randomization. Following randomization, the patient will be given either 50 mg oral indomethacin with two pills of placebo, or 3 pills each containing 10 mg oral nifedipine for a total of 30 mg. The patients will then receive either 25 mg of oral indomethacin every 6 hours for 48 hours, or 20 mg of oral nifedipine every 6 hours for 48 hours. Tocolysis beyond 48 hours will not be used.

Condition Intervention
Obstetric Labor, Premature
Drug: Indomethacin
Drug: Nifedipine

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Indocin Versus Nifedipine for Preterm Labor Tocolysis - A Randomized Double-Blinded Clinical Trial

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Recurrent preterm labor within two weeks of randomization [ Time Frame: Two weeks after enrolled and randomized ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Birth weight, gestational age, delay of delivery, neonatal morbidities, maternal side effects, time to uterine quiescence [ Time Frame: Discharge of mother and neonate ] [ Designated as safety issue: No ]

Estimated Enrollment: 110
Study Start Date: April 2007
Estimated Study Completion Date: September 2016
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Indomethacin
50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.
Drug: Indomethacin
One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.
Active Comparator: Nifedipine
30 mg Nifedipine initially followed by 10 mg every 6 hrs for 48 hrs.
Drug: Nifedipine
Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Singleton and twin gestations
  • Intact amniotic membranes
  • No contra-indications to tocolysis
  • 24-34 weeks gestation by last menstrual period and/or ultrasound
  • Documented cervical change, and regular painful uterine contractions at least every 5 minutes, or at least 2 cm cervical dilation and 80% effacement

Exclusion Criteria:

  • Ruptured amniotic membranes
  • Signs/symptoms of chorioamnionitis (maternal temperature greater than 100.4 F/38.0 C, fetal tachycardia, uterine tenderness)
  • Non-reassuring fetal heart rate tracings
  • Contra-indications to indomethacin or nifedipine
  • Contra-indications to tocolysis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00486824

Contact: Deirdre J Lyell, MD (650) 736-1191

United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Deirdre J Lyell, MD    650-736-1191   
Contact: Yair Blumenfeld, MD    (650) 269-4665   
Principal Investigator: Deirdre Judith Lyell         
Sponsors and Collaborators
Stanford University
Principal Investigator: Deirdre Judith Lyell Stanford University
  More Information

Responsible Party: Stanford University Identifier: NCT00486824     History of Changes
Other Study ID Numbers: 97873 
Study First Received: June 13, 2007
Last Updated: November 18, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Gout Suppressants
Tocolytic Agents
Reproductive Control Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Calcium Channel Blockers
Membrane Transport Modulators
Vasodilator Agents processed this record on October 27, 2016